Prostate cancer hormone drug level monitoring study
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how levels of common prostate cancer hormone treatments (abiraterone, apalutamide, darolutamide, or enzalutamide) stay in your blood over time. By checking drug levels, doctors hope to personalize dosing to make treatment safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking abiraterone, apalutamide, darolutamide, or enzalutamide for prostate cancer.
- You have been on the medication long enough for the drug levels to be steady in your blood (usually at least 2 weeks).
- You are 18 years or older.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This Phase 2 study tests whether adding apalutamide to standard hormone therapy (ADT) after prostate surgery can lower the chance that prostate cancer comes back. It targets men at higher risk of recurrence based on PSA levels and a risk score from surgical findings.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.